Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po


Iskalni niz: "avtor" (Simona Borštnar) .

1 - 10 / 93
Na začetekNa prejšnjo stran12345678910Na naslednjo stranNa konec
Cepiva proti raku dojk : izzivi in preboji ter zasnova slovenske raziskave
Simona Borštnar, 2024, objavljeni strokovni prispevek na konferenci

Ključne besede: internistična onkologija, rak dojk, cepiva
Objavljeno v DiRROS: 19.04.2024; Ogledov: 107; Prenosov: 28
.pdf Celotno besedilo (953,19 KB)

Dnevi internistične onkologije 2024 : inovativna zdravila v onkologiji
2024, zbornik strokovnih ali nerecenziranih znanstvenih prispevkov na konferenci

Objavljeno v DiRROS: 04.04.2024; Ogledov: 198; Prenosov: 70
.pdf Celotno besedilo (9,80 MB)

Triple negative breast cancer : prognostic factors and survival
Tanja Ovčariček, Snježana Frković-Grazio, Erika Matos, Barbara Možina, Simona Borštnar, 2011, izvirni znanstveni članek

Povzetek: Background. Triple negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progesteron(PgR) receptors as well as human epidermal growth factor receptor 2 (HER2). Our retrospective analysis addressed prognostic factors for short- and long-term outcomes of patients (pts) with TNBC pts treated in routine clinical practice. Patient and methods.Our retrospective study included 269 TNBC treated at Institute of Oncology Ljubljana between March 2000 and December 2006. The collected data included patientsć, tumoursć and treatmentsć characteristics. The survival analyses were performed using the Kaplan-Meier method. The Cox proportional hazard model was used in the multivariate analysis. Results. The median age ofour patients was 55.3 yrs (23-88.5) and the median follow-up was 5.9 yrs (0.3-9.6). Six (2%) pts experienced local only, 79 (92%) pts distal recurrenceand 66 (24%) died. The predominant localisation of the first relapsewas in visceral organs (70.4%). The 5-year disease-free survival (DFS) for the entire group was 68.2% and the 5-year overall survival (OS) was 74.5%.We found a pattern of high recurrence rate in the first 3 years following the diagnosis and a clear decline in recurrence rate over the next 3years. In the univariate analysis age, nodal status, size and lymphovascular invasion (LVI) were found to have a significant impact on DFS as well as on OS. In the multivariate analysis only age (HR=1.79; 95%CI=1.14-2.82; p=0.012) and nodal status (HR=2.71; 95%CI=1.64-4.46; p<0.001) retained their independent prognostic value for DFS and for OS only the nodal status (HR=2.96; 95%CI=1.51-5.82; p=0.002). (Abstract truncated at 2000 characters)
Objavljeno v DiRROS: 19.03.2024; Ogledov: 134; Prenosov: 38
.pdf Celotno besedilo (536,99 KB)

Rituximab affects the prognosis of patients with nonHodgkin's lymphomas
Barbara Jezeršek Novaković, Marjeta Vovk, Simona Borštnar, Radka Tomšič, 2004, izvirni znanstveni članek

Povzetek: Backround. Rituximab - the most widely used monoclonal antibody in the B cell lymphoid malignancies has been applied successfully in the treatment of relapsed and refractory indolent CD20 positive B cell lymphomas and more recently, also in the treatment of aggressive lymphomas in combination with standard chemotherapy. Albeit the chemo-immunotherapy has a wide range of potential applications, there are still several issues that have to be resolved: (1) the optimal scheduling of antibody-chemotherapy combinations, (2) the most active of these combinations, as well as (3) the predictors of response to rituximab. Patients and methods. To facilitate addressing the first two questions, we performed an analysis in 25 patients with different histological types of CD20 positive nonHodgkin's lymphomas (10 aggressive and 15 indolent). Seventeen patients were treated with chemo-immunotherapy for a relapse, and just in 8 patients rituximab was added to first line chemotherapy. Most of the responders received the CHOP regimen, but also otherregimens (FC, BVCPP) were effective in combination with rituximab. Results. The overall response rate was 76%, with 68% complete remissions. The median response duration has not been reached yet. The response was markedly better in the group of previously untreated patients, where the overall response rate reached 100%, with 7 patients in complete and 1 patient in partial remission. Most of the treatment failures occurred in heavily pretreated patients with aggressive lymphomas. No serious adverse effects wereobserved. Conclusion The chemo-immunotherapy improves the treatment outcomes in patients with untreated and relapsed CD20 positive nonHodgkin's lymphomas in comparison to chemotherapy alone. The combined treatment is the most effective when used as soon as possible (preferably as the first line treatment). (Abstract truncated at 2000 characters).
Objavljeno v DiRROS: 07.02.2024; Ogledov: 240; Prenosov: 50
.pdf Celotno besedilo (4,61 MB)

Prognostic relevance of urokinase plasminogen activator and its inhibitors in patients with breast cancer
Simona Borštnar, Tanja Čufer, Ivan Vrhovec, Zvonimir Rudolf, 1999, izvirni znanstveni članek

Povzetek: Urokinase plasminogen activator (uPA) and its inhibitors, PAI-1 and PAI-2, play an important role in iritercellular tissue degradation, thus promoting tumor cell invasion into the adjoining structures and metastasizing. Our studywas aimed to assess a possible prognostic value of uPA, PAI-1 and PAI-2 in a retrospective series of 87 patients with breast cancer stage I-III, whosecytosols were stored in the archives of the, Institute of Oncology in Ljubljana. The median follow-up was 35 months. The prognostic value of the established prognostic factors and uPA, PAI-1 and PAI-2 were evaluated by means of univariate statistical analysis and partial multivariate models. The obtained uPA values were very low and did not correlate with the disease free survival, whereas PAI-1 and PAI-2 significantly influenced the time to the first recurrence. Patients with PAI-1 values above 5 ng/mg proteins had statistically significantly worse disease free survival than the patients withlower PAI-1 values (58% vs. 85%). In the case of PAI-2, the situation wasjust the opposite: the patients with PAI-2 values exceeding 6.4 ng/mg proteins had statistically significantly better 3-year disease free survival than the patients with lower values (90% vs. 60%). Both, PAI-1 and PAl-2 retained their independent prognostic value, irrespective of the addition of the established prognostic factors to partial multivariate models, and only with locally advanced disease the prognostic value of PAI-1 was greater than that of PAI-2.
Objavljeno v DiRROS: 22.01.2024; Ogledov: 221; Prenosov: 52
.pdf Celotno besedilo (548,70 KB)

The urokinase-type plasminogen activator, its inhibitors and its receptor - the new prognostic factors in solid cancers
Simona Borštnar, Tanja Čufer, Zvonimir Rudolf, 1997, pregledni znanstveni članek

Povzetek: The urokinase-type plasminogen activator (uPA), its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR) play nan important role in the degradation of the intercellular tissue, the process which affects the ability of cancer cells to invade to surrounding tissue and to metastasize. The results of clinical studies performed in the past few years point out a significant influence of uPA, PAI-1, PAI-2 and uPAR on the course of the disease and survival of patients with solid tumours, particularly breast cancer. Hopefullythe categorization of patients according to the content of the serineproteases and its inhibitors in tumour tissues could provide a basis formore rational treatment planning and thus improving patients' survival.
Objavljeno v DiRROS: 18.01.2024; Ogledov: 194; Prenosov: 52
.pdf Celotno besedilo (485,80 KB)

Differential diagnosis between bone metastases and osteomalacia
Branko Zakotnik, Simona Borštnar, Tadeja Movrin, Boris Jančar, Andreja Zidar, 1996, izvirni znanstveni članek

Povzetek: In oncology the diagnosis of skeletal metastases is a frequent one, in infact so frequent that other diagnoses such as metabolic bone diseases affecting patients with cancer may be overlooked. In our report two cases of osteomalacia referred to an oncologist are presented; in both of them the diagnosis of diffuse bone metastases of unknown origin was suspected. The differential diagnosis is discussed and the importance of bone marrow biopsy using Yamshidi needle for diagnosis of metabolic bone disease is emphasized.
Objavljeno v DiRROS: 16.01.2024; Ogledov: 203; Prenosov: 49
.pdf Celotno besedilo (318,84 KB)

Pristopi k zdravljenju raka dojk
Simona Borštnar, 2023, objavljeni strokovni prispevek na konferenci

Ključne besede: rak dojk, zdravljenje, sistemsko zdravljenje
Objavljeno v DiRROS: 08.01.2024; Ogledov: 215; Prenosov: 61
.pdf Celotno besedilo (354,25 KB)

Iskanje izvedeno v 0.26 sek.
Na vrh